Please complete this form relating to your transactions for Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) securities between between September 20, 2017 and September 12, 2018, both dates inclusive (the “Class Period”).
You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at email@example.com, or you may click here to print a PDF of this form.
On September 26, 2018, the initial complaint in this securities class action was filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”), and certain of Alnylam’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action lawsuit brought on behalf of all persons or entities who purchased or otherwise acquired the securities of Alnylam from September 20, 2017 through September 12, 2018, both dates inclusive (the “Class Period”).
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
On July 3, 2019, Lead Plaintiffs filed an amended complaint (the “Amended Complaint). Defendants filed a Motion to Dismiss the Amended Complaint on July 31, 2019. On March 23, 2020, the Court issued an Order granting Defendants' Motion to Dismiss. On June 1, Lead Plaintiffs requested permission from the Court to amend the Amended Complaint. Defendants’ opposed Lead Plaintiffs’’ request. On March 12, 2021, the Court issued an Order denying Plaintiffs’ Motion to Amend the Amended Complaint. This action has concluded.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at firstname.lastname@example.org. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.